Clinical Trials Logo

Filter by:
NCT ID: NCT00702832 Completed - Nausea Clinical Trials

Effect of Vestibular Rehabilitation - a Randomized Controlled Trial

Start date: January 2008
Phase: N/A
Study type: Interventional

The aim of this study is to assess if early supported vestibular rehabilitation can reduce dizziness and improve daily life activities in patients with acute vestibular injury. The study question is: Does early supported vestibular rehabilitation have an additional effect on dizziness symptoms and daily life functions compared to standard treatment?

NCT ID: NCT00702078 Completed - COPD Clinical Trials

Home-based Treatment of Patients With Chronic Obstructive Pulmonary Disease (COPD)

COPD-HOME
Start date: April 2008
Phase: N/A
Study type: Interventional

We want to improve the treatment of patients suffering from COPD (3-4) by early medical intervention in the patients home. A close cooperation between the hospital and the primary healthcare system will hopefully reduce hospitalisation, drug consumption and improve quality of life. Following up from the hospital and the primary healthcare in cooperation may lead to earlier detection and treatment of exacerbations in COPD. The main outcome variable will be number of hospitalizations assessed simply by counting. The second objective will be Quality of life and activation assessed by different questionnaires included in St.George´s Respiratory Questionnaire.

NCT ID: NCT00702065 Completed - Multiple Sclerosis Clinical Trials

A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment

MusiQoL
Start date: November 2007
Phase: N/A
Study type: Observational

This is a multi-center, multi-regional observational,24 month study. Health-related quality of life data from the MusiQoL instrument and SF-36 instrument will be collected at baseline, M6, M12, M18 and M24 in patients with MS. In addition, physical health outcomes such as expanded disability status scores (EDSS) will be collected every 6 months.

NCT ID: NCT00701415 Completed - Fabry Disease Clinical Trials

A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms

FIELD
Start date: September 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether 2 alternative dosing regimens of Fabrazyme (agalsidase beta) (1.0 mg/kg every 4 weeks or 0.5 mg/kg every 2 weeks) are effective in treatment-naïve pediatric patients without severe symptoms. Patients will be treated for 5 years.

NCT ID: NCT00701363 Completed - Acromegaly Clinical Trials

Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects

LEAD
Start date: October 2008
Phase: Phase 4
Study type: Interventional

The purpose of the study is to assess the efficacy of an extended injection interval schedule of lanreotide Autogel 120 mg in acromegalic subjects who are biochemically controlled on long term treatment with octreotide LAR 10 or 20 mg

NCT ID: NCT00700609 Terminated - Depressive Disorder Clinical Trials

Family Based Treatment of Depressed Adolescents

BudFam
Start date: June 2008
Phase: Phase 2
Study type: Interventional

The purpose of this project is to assess the effectiveness of a family-based therapy (Attachment based family therapy-ABFT) for Norwegian adolescents (13-17 years) referred to specialist mental heath clinics.

NCT ID: NCT00700102 Completed - Colorectal Cancer Clinical Trials

A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.

Start date: February 2006
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of adding bevacizumab to crossover fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer who have experienced disease progression under first line treatment with standard chemotherapy plus bevacizumab. Participants will receive chemotherapy alone, or in combination with bevacizumab. The anticipated time on study treatment is until disease progression or unacceptable toxicity occurs. Participants are allowed to continue on bevacizumab, even after stopping chemotherapy.

NCT ID: NCT00699751 Completed - Bone Metastases Clinical Trials

A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases

ALSYMPCA
Start date: June 2008
Phase: Phase 3
Study type: Interventional

ALSYMPCA (ALpharadin in SYMPtomatic Prostate CAncer) is an international Phase III clinical study to evaluate the efficacy and safety of Radium-223 dichloride in patients with hormone refractory prostate cancer and skeletal metastases.

NCT ID: NCT00699114 Completed - Surgery Clinical Trials

Analgesic Effect of Ibuprofen, Paracetamol (Acetaminophen), and Paracetamol (Acetaminophen) Plus Codeine on Acute Pain

Start date: June 2007
Phase: Phase 4
Study type: Interventional

The purpose of this placebo controlled clinical trial is to evaluate the dose response relationship of ibuprofen in doses from 400 mg to 800 mg and paracetamol (acetaminophen)in doses from 500 mg to 1000 mg compared with paracetamol (acetaminophen)1000 mg plus codeine 60 mg on acute postoperative pain after surgical removal of impacted third molars.

NCT ID: NCT00698672 Active, not recruiting - Arthritis Clinical Trials

RSA-Study of Cemented Hip Prostheses With Five Different Articulations

Start date: November 2004
Phase: N/A
Study type: Interventional

The purpose of this study is to compare wear and migration of the following hip prostheses: 1. Charnley monoblock 22.2mm caput and OGEE polyethylene acetabular component 2. Spectron EF stem with Reflection polyethylene cup and 28 mm CoCr caput 3. Spectron EF stem with XLPE cup and 28 mm CoCr caput 4. Spectron EF stem with Reflection polyethylene cup and 28 mm Oxinium caput 5. Spectron EF stem with XLPE cup and 28 mm Oxinium caput